Rony Sayegh

Dr. Rony Sayegh

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
RSRony Sayegh
Rony Sayegh
LALeonard P.K. Ang
Leonard P.K. Ang
CFC. Stephen Foster
C. Stephen Foster
CDClaes H. Dohlman
Claes H. Dohlman

1 February 2010 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
RSRony Sayegh
Rony Sayegh
LDLinda Avena Diaz
Linda Avena Diaz
FVFernando Vargas-Martín
Fernando Vargas-Martín
RWRobert H. Webb
Robert H. Webb
CDClaes H. Dohlman
Claes H. Dohlman
EPEli Peli
Eli Peli
Purpose.: To evaluate the optical characteristics of the Boston Keratoprosthesis (KPro), identify glare sources, evaluate possible glare control, and examine the benefit of implantation when the fellow eye has normal vision. Methods.: Computed and optical-bench-measured point spread function (PSF) and glare sources were compared. A translucent plastic cornea was used to determine the impact of glare caused by scatter in the cornea and its control with a dark-iris tinted contact lens. The effect of glare in implanted eyes was measured with a brightness acuity test (BAT), with and without the dark-iris contact lens. Computed and measured visual fields were compared. Stereopsis was measured in patients with an intact fellow eye. Results.: Computed and measured modulation transfer functions for the KPro were found to be very close to the diffraction limit. Both the model-eye measurements and patients' BAT glare responses identified that the hazy corneal graft surrounding the KPro is the main source of glare and can be controlled with a dark-iris contact lens. The lid effectively blocks the light that would be scattered in the hazy cornea of patients in whom the type II KPro was implanted. An intact fellow eye remains the dominant eye, with better acuity, and the KPro eye supports only minimal stereo ability and does not expand the binocular visual field. Conclusions.: Glare can be reduced significantly with the use of a contact lens with a dark iris. Implanting the KPro in a patient whose fellow eye has normal or near normal vision does not seem to improve visual function.

1 April 2020 in The Ocular Surface
Verified
Journal Article
Closed access
ASAndrew N. Siedlecki
Andrew N. Siedlecki
SSScott D. Smith
Scott D. Smith
ASAdam R. Siedlecki
Adam R. Siedlecki
SHSalim M. Hayek
Salim M. Hayek
RSRony Sayegh
Rony Sayegh

1 January 2013 in International Ophthalmology Clinics
Verified
Journal Article
Closed access
CHCecily E. Hamill
Cecily E. Hamill
SBSara Bozorg
Sara Bozorg
HCHan-Ying Peggy Chang
Han-Ying Peggy Chang
HLHyunjoo Lee
Hyunjoo Lee
RSRony Sayegh
Rony Sayegh
JCJames Chodosh
James Chodosh

14 December 2015 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
SHSalim M. Hayek
Salim M. Hayek
JSJennifer A. Sweet
Jennifer A. Sweet
JMJonathan P. Miller
Jonathan P. Miller
RSRony Sayegh
Rony Sayegh
Objective. To describe the successful treatment of refractory corneal neuropathic pain with neuromodulation techniques. Design. Single case report. Setting. Academic tertiary care center in the United States of America. Subject and Methods. A 30-year-old woman presented with a 7-year history of refractory bilateral keratoneuralgia following laser-assisted in-situ keratomileusis (LASIK) procedure on both eyes. Having failed all conservative measures, the patient initially underwent trigeminal nerve stimulation and subsequently was implanted with an intrathecal drug delivery system (IDDS) with the catheter placed at the level C1. Results. Following an initial favorable response to the trigeminal nerve stimulator, the pain became refractory to neurostimulation after a few months and the system was explanted. The patient was successfully trialed with an intrathecal catheter placed at the level of C1 delivering a combination of bupivacaine and low dose fentanyl. The patient was then implanted with an IDDS equipped with a patient-activated bolus system. The patient was very satisfied with the treatment and has had greater than 50% pain relief for over a year. Conclusions. Intrathecal delivery of bupivacaine and low dose fentanyl in the upper cervical spine can be effective in controlling refractory eye pain in properly selected patients and treatment centers.

1 December 2006 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
FTFaisal M. Tobaigy
Faisal M. Tobaigy
RGRamon C. Ghanem
Ramon C. Ghanem
RSRony Sayegh
Rony Sayegh
JHJoelle A. Hallak
Joelle A. Hallak
DADimitri T. Azar
Dimitri T. Azar